title: Equol an isoflavonoid: potential for improved prostate health, in vitro and in vivo evidence.
abstract: BACKGROUND
  To determine: in vitro binding affinity of equol for 5alpha-dihydrotestosterone (5alpha-DHT), in vitro effects of equol treatment in human prostate cancer (LNCap) cells, and in vivo effects of equol on rat prostate weight and circulating levels of sex steroid hormones.
  
  
  METHODS
  First, in vitro equol binding affinity for 5alpha-DHT was determined using 14C5alpha-DHT combined with cold 5alpha-DHT (3.0 nM in all samples). These steroids were incubated with increasing concentrations of equol (0-2,000 nM) and analyzed by Sephadex LH-20 column chromatography. 14C5alpha-DHT peak/profiles were determined by scintillation counting of column fractions. Using the 14C5alpha-DHT peak (0 nM equol) as a reference standard, a binding curve was generated by quantifying shifts in the 14C5alpha-DHT peaks as equol concentrations increased. Second, equol's in vitro effects on LNCap cells were determined by culturing cells (48 hours) in the presence of increasing concentrations of dimethyl sulfoxide (DMSO) (vehicle-control), 5alpha-DHT, equol or 5alpha-DHT+equol. Following culture, prostate specific antigen (PSA) levels were quantified via ELISA. Finally, the in vivo effects of equol were tested in sixteen male Long-Evans rats fed a low isoflavone diet. From 190-215 days, animals received 0.1 cc s.c. injections of either DMSO-control vehicle (n = 8) or 1.0 mg/kg (body weight) of equol (in DMSO) (n = 8). At 215 days, body and prostate weights were recorded, trunk blood was collected and serum assayed for luteinizing hormone (LH), 5alpha-DHT, testosterone and 17beta-estradiol levels.
  
  
  RESULTS
  Maximum and half maximal equol binding to 5alpha-DHT occurred at approximately 100 nM and 4.8 nM respectively. LNCap cells cultured in the presence of 5alpha-DHT significantly increased PSA levels. However, in the presence of 5alpha-DHT+equol, equol blocked the significant increases in PSA levels from LNCap cells. In vivo equol treatment significantly decreased rat prostate weights and serum 5alpha-DHT levels but did not alter LH, testosterone, and estradiol levels.
  
  
  CONCLUSIONS
  Equol administration appears to have potential beneficial effects for prostate health and other 5alpha-DHT mediated disorders. Equol administration: reduces PSA levels from LNCap cells under 5alpha-DHT stimulation, decreases rat prostate size, decreases serum 5alpha-DHT levels and androgen hormone action, while not altering other circulating sex steroids or LH levels.
authors.affiliation: Stoelting Co., Wood Dale, IL 60191, USA.
authors.forename: Trent D
authors.initials: TD
authors.lastname: Lund
authors.forename: Crystal
authors.initials: C
authors.lastname: Blake
authors.forename: Lihong
authors.initials: L
authors.lastname: Bu
authors.forename: Amy N
authors.initials: AN
authors.lastname: Hamaker
authors.forename: Edwin D
authors.initials: ED
authors.lastname: Lephart
mesh_terms: D000818:Animals; D045744:Cell Line, Tumor; D013196:Dihydrotestosterone / Q000037:antagonists & inhibitors / Q000378:metabolism; D060754:Equol; D006801:Humans; D007529:Isoflavones / Q000378:metabolism* / Q000494:pharmacology; D008297:Male; D011467:Prostate / Q000187:drug effects / Q000378:metabolism*; D017430:Prostate-Specific Antigen / Q000037:antagonists & inhibitors; D011471:Prostatic Neoplasms / Q000378:metabolism*; D051381:Rats
chemical_list: C007610:4',7-dihydroxy-3,4-dihydroisoflavone; D007529:Isoflavones; D013196:Dihydrotestosterone; D060754:Equol; D017430:Prostate-Specific Antigen